Current and emerging pharmacotherapeutic options for irritable bowel syndrome

Jose L. Barboza, Nicholas J. Talley, Baharak Moshiree

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the μ-opioid receptor (agonists and antagonists), selective κ-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.

Original languageEnglish
Pages (from-to)1849-1870
Number of pages22
JournalDrugs
Volume74
Issue number16
DOIs
StatePublished - Jan 1 2014

Fingerprint

Irritable Bowel Syndrome
Serotonin Agents
Therapeutics
Narcotic Antagonists
Patient Preference
Primary Care Physicians
Opioid Receptors
Population Characteristics
Bile Acids and Salts
Patient Selection
Anti-Inflammatory Agents
Randomized Controlled Trials
Pharmacology
Safety
Costs and Cost Analysis
Food
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Current and emerging pharmacotherapeutic options for irritable bowel syndrome. / Barboza, Jose L.; Talley, Nicholas J.; Moshiree, Baharak.

In: Drugs, Vol. 74, No. 16, 01.01.2014, p. 1849-1870.

Research output: Contribution to journalArticle

Barboza, JL, Talley, NJ & Moshiree, B 2014, 'Current and emerging pharmacotherapeutic options for irritable bowel syndrome', Drugs, vol. 74, no. 16, pp. 1849-1870. https://doi.org/10.1007/s40265-014-0292-7
Barboza, Jose L. ; Talley, Nicholas J. ; Moshiree, Baharak. / Current and emerging pharmacotherapeutic options for irritable bowel syndrome. In: Drugs. 2014 ; Vol. 74, No. 16. pp. 1849-1870.
@article{2785105e1a734a81949ede2b25f31b8b,
title = "Current and emerging pharmacotherapeutic options for irritable bowel syndrome",
abstract = "Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the μ-opioid receptor (agonists and antagonists), selective κ-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.",
author = "Barboza, {Jose L.} and Talley, {Nicholas J.} and Baharak Moshiree",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40265-014-0292-7",
language = "English",
volume = "74",
pages = "1849--1870",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "16",

}

TY - JOUR

T1 - Current and emerging pharmacotherapeutic options for irritable bowel syndrome

AU - Barboza, Jose L.

AU - Talley, Nicholas J.

AU - Moshiree, Baharak

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the μ-opioid receptor (agonists and antagonists), selective κ-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.

AB - Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the μ-opioid receptor (agonists and antagonists), selective κ-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.

UR - http://www.scopus.com/inward/record.url?scp=84921935845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921935845&partnerID=8YFLogxK

U2 - 10.1007/s40265-014-0292-7

DO - 10.1007/s40265-014-0292-7

M3 - Article

C2 - 25260888

AN - SCOPUS:84921935845

VL - 74

SP - 1849

EP - 1870

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 16

ER -